Clinical Gastroenterology and Hepatology
Volume 8, Issue 1 , Pages 42-48.e1, January 2010

Citalopram Provides Little or No Benefit in Nondepressed Patients With Irritable Bowel Syndrome

  • Uri Ladabaum

      Affiliations

    • Division of Gastroenterology, University of California, San Francisco, California
    • Department of Medicine, University of California, San Francisco, California
    • Corresponding Author InformationReprint requests Address requests for reprints to: Uri Ladabaum, MD, MS, Division of Gastroenterology, S-357, Box 0538, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, California 94143-0538. fax: (415) 502-6714
    • ,
  • Annie Sharabidze

      Affiliations

    • Division of Gastroenterology, University of California, San Francisco, California
    • Department of Medicine, University of California, San Francisco, California
    • ,
  • Theodore R. Levin

      Affiliations

    • Kaiser Permanente Division of Research, Oakland, California
    • ,
  • Wei K. Zhao

      Affiliations

    • Kaiser Permanente Division of Research, Oakland, California
    • ,
  • Elaine Chung

      Affiliations

    • Kaiser Permanente Division of Research, Oakland, California
    • ,
  • Peter Bacchetti

      Affiliations

    • Department of Epidemiology and Biostatistics, University of California, San Francisco, California
    • ,
  • Chengshi Jin

      Affiliations

    • Department of Epidemiology and Biostatistics, University of California, San Francisco, California
    • ,
  • Barbara Grimes

      Affiliations

    • Department of Epidemiology and Biostatistics, University of California, San Francisco, California
    • ,
  • Craig J. Pepin

      Affiliations

    • The Polyclinic, Seattle, Washington

published online 18 September 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  View this article's video abstract at www.cghjournal.org.

     Conflicts of interest The authors disclose the following: Dr Ladabaum is on the Speaker Bureaus of Novartis, Sucampo, and Takeda. The remaining authors disclose no conflicts.

     Funding This study was supported by a National Institutes of Health grant M01-RR00079, including a Clinical Associate Physician Award to Dr Ladabaum, National Institutes of Health/National Center for Research Resources (NCRR) University of California, San Francisco-Clinical and Transational Studies Institute (CTSI) grant number UL1 RR024131, and an AGA/Solvay Award for Clinical Research in Irritable Bowel Syndrome/Motility.

    PII: S1542-3565(09)00891-X

    doi:10.1016/j.cgh.2009.09.008

    Clinical Gastroenterology and Hepatology
    Volume 8, Issue 1 , Pages 42-48.e1, January 2010